American Riviera
You are here:  Home  >  Biotech  >  Current Article

Biotech giant Amgen bails on brain research

By   /   Friday, November 1st, 2019  /   Comments Off on Biotech giant Amgen bails on brain research

    Print       Email
Amgen announced its exit from neurology research as sales slumped in its third quarter, while higher net income and stock buybacks propelled earnings per share up 14 percent. Despite the initial success of its migraine treatment Aimovig, the Thousand Oaks biotech giant announced its intention to call off early forays into neuroscience research, shifting its…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Bank of the Sierra reports earnings growth for Q4 and full year of 2021

Read More →